LBA67 – Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study
Antoine Italiano (Bordeaux, FR)
Patients with relapsed and unresectable high-grade osteosarcoma (OS) and Ewing sarcoma (ES) have had a dismal and unchanging prognosis over the last decades. There are currently no approved drugs for this challenging setting but pharmacologic inhibition of MET signaling and of aberrant angiogenesis has shown promise in pre-clinical OS and ES models. This late-breaking abstract suggests that carbozantinib has shown meaningful clinical activity in OS and ES patients with heavily pre-treated advanced disease and reached the primary efficacy endpoints in both the OS and ES cohorts.
1603O – Initial results of phase 1 study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
Suzanne George (Boston, US)
DCC-2618 is a switch control inhibitor which broadly inhibits mutations in the KIT exons 9,11,13, 14, 17 and 18. Results presented at ESMO 2018 suggest that DCC-2618 demonstrated encouraging clinical benefit and a favorable tolerability profile in GIST pts treated in the 2nd line or later. Initiation of a second Phase 3 study for this agent in 2nd line GIST pts is anticipated by the end of 2018.